FDA Purple Book · Reference family
amivantamab-vmjw (Rybrevant)
amivantamab-vmjw is an FDA-licensed reference biologic from Janssen Biotech, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2021
Reference approved
Reference product
351(a)BLA 761210
Rybrevant amivantamab-vmjw
Janssen Biotech, Inc.
- Approved
- May 21, 2021
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for amivantamab-vmjw, in chronological order.
Reference approval
Approval date of the reference amivantamab-vmjw product.
5 yr 1 mo ago
Frequently asked questions
Are there biosimilars approved for amivantamab-vmjw (Rybrevant)?
No 351(k) biosimilars or interchangeable biosimilars referencing amivantamab-vmjw are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.